

ASX ANNOUNCEMENT

23 May 2023

2023 Annual Meeting of Stockholders President & CEO's Presentation

Sunnyvale, California; 23 May 2023: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), is pleased to provide the President & CEO's presentation to be delivered at the Company's virtual 2023 Annual Meeting of Stockholders today, Tuesday, 23 May 2023 at 9:00am Australian Eastern Standard Time (Monday, 22 May 2023 at 4:00pm U.S. Pacific Daylight Time).

To attend the Annual Meeting, enter meetnow.global/MFKV9LA into a web browser on your computer or other device with web access:

- CHESSE Depositary Interest (CDI) holders will need to select “Guest” and enter their name and email address;
- Shareholders will need to select “Stockholder” and enter their Shareholder Control Number which will have been provided by Computershare Investor Services; and
- Proxyholders (including CDI holders who have appointed themselves as CHESSE Depositary Nominees Pty Ltd's¹ (CDN's) proxy) will need to select “Invitation” and enter a proxy number which will have been provided by Computershare Investor Services.

Further information in relation to the Annual Meeting is set out in the Notice of Annual Meeting of Stockholders.

ENDS

This announcement has been authorised for release by the EBR Systems General Disclosure Committee, a committee of the Board of Directors.

For more information, please contact:

Company

John McCutcheon
President & CEO
P: +1 408 720 1906
E: info@ebrsystemsinc.com

Investors

Dean Dribbin
Vesparum Capital
P: +61 3 8582 4800
E: EBRSystems@vesparum.com

About EBR Systems (ASX: EBR)

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

¹ CHESSE Depositary Nominees Pty Ltd is the holder of record for all shares beneficially owned by holders of CDIs.

EBR Systems' WiSE® Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.



AGM Presentation

May 2023

Year in Review

June 2022

- Completed interim enrolment in pivotal SOLVE-CRT trial
- Secured US\$50M growth capital facility with Runway Growth Finance

August 2022

- Clinical study of WiSE published in Heart Rhythm Journal

January 2023

- Engaged with retail investors on an Australian roadshow

February 2023

- Appointed Dr. Rick Kuntz as consulting Chief Scientific Officer
- SOLVE-CRT 6 Month follow up completed for final patient

March 2023

- SOLVE-CRT presentation data accepted into the Heart Rhythm Society conference

May 2023

- Pivotal SOLVE-CRT study results presented at the Heart Rhythm Society conference



Journey from here

EBR continues to achieve significant value catalysts and pave the way to future value creation

2022

- ✓ Complete SOLVE-CRT pivotal trial enrolment
- ✓ Support clinical sites and patient implants
- ✓ Presentations at cardiology conferences; publications in medical journals

2023

- ✓ SOLVE-CRT 6 Month follow up completed for final patient in February 2023
- ✓ **Headline data released at Heart Rhythm Society conference**
- ✓ **Positive trial data unlocks second tranche of growth capital facility**
- ✓ **Finalise clinical data submission to the FDA**
- ✓ Submit manuscript to medical journal for peer-review publication

2024+

- ❑ Submit Clinical Module for PMA application to the FDA
- ❑ Submit Final Module including transmitter upgrades
- ❑ FDA approval in the US
- ❑ Commercial launch in the US
- ❑ Launch in select markets OUS¹ as reimbursement and regulatory coverage is secured
- ❑ Expand use of WiSE[®] into new patient groups and geographies

Attractive investment opportunity

EBR is focused on executing its clear and targeted commercialisation strategy to deliver shareholder value

De-risked pathways to market



Pivotal trial

Pivotal trial results released
WiSE Breakthrough Device Designation granted by FDA



Well funded

Funding flexibility to progress regulatory and commercial objectives



Large markets

Targeting initial addressable market of US\$2.5bn with significant upside



Unique solution

No competition as WiSE® is complementary to other leadless devices



Re-rate potential

Value upside exists as EBR continues progress towards first sales / revenues

Disclaimer

The material contained in this document is a presentation of general information about the activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries (“EBR”) current as at the date of this presentation. It should be read in conjunction with EBR’s periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at www.asx.com.au.

The information in this presentation is provided in a summary form, does not purport to be complete and should not be relied upon as advice for investment purposes. This presentation is for information purposes only and is not financial product advice or a recommendation to acquire EBR securities. This presentation does not take into account the investment objectives, financial position or needs of any particular investor. Independent advice should be sought before making any investment decision.

The information in this presentation has been prepared by EBR in good faith and with due care, but the EBR does not make any representation or warranty, express or implied, as to the fairness, accuracy, correctness or completeness of the information, opinions or conclusions contained in this presentation. The information in this presentation is subject to change without notice and unless required by law, EBR assumes no obligation to update this presentation or its contents for any matter arising or coming to EBR’s notice after the date of this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management’s current expectations and beliefs. Such statements are typically identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, ‘anticipates’, ‘intends’ and other similar words. These statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate. Actual results

may differ materially from what is expressed in this presentation.

To the maximum extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining to act as a result of this presentation or its contents is accepted by EBR or any of its officers, employees or agents.

The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction.

Investors should note that this presentation may contain unaudited financial information that has been prepared by EBR’s management. EBR’s results are reported under US GAAP. Certain financial data in this presentation is “non-IFRS financial information” under Regulatory Guide 230 (Disclosing non-IFRS financial information) published by ASIC. All values are stated in U.S. dollars unless otherwise stated.

EBR’s CHES Depositary Interests (“CDIs”) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.



Contact Us

Company

John McCutcheon
President & CEO
P: +1 408 720 1906
E: info@ebrsystemsinc.com

Investors

Dean Dribbin
Vesparum Capital
P: +61 3 8582 4800
E: EBRSystems@vesparum.com